IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. - Wikidata - awgldk - TriplyDB

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

http://www.wikidata.org/entity/Q34655376

about

Rivastigmine for Alzheimer's disease Rivastigmine for Alzheimer's disease Rivastigmine for Alzheimer's disease Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Update on the pharmacological treatment of Alzheimer's disease Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics Acetylcholinesterase inhibitors: pharmacology and toxicology.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results.The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Alzheimer's disease: a clinical practice-oriented review.Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice.Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities Real-world evaluation of compliance and preference in Alzheimer's disease treatment.Synthesis and in silico evaluation of 1N-methyl-1S-methyl-2-nitroethylene (NMSM) derivatives against Alzheimer disease: to understand their interacting mechanism with acetylcholinesterase.Compliance and Caregiver Satisfaction in Alzheimer's Disease: Results from the AXEPT Study.Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time.Management of patients with Alzheimer's disease: pharmacological treatment and quality of life Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan.Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease Relative tolerability of Alzheimer's disease treatments Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle.Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.Treatment of dementia with Lewy bodies and Parkinson's disease dementia.Pharmacological treatment of Alzheimer disease.Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic review Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.

P2860

Q24186551-7F0F4AAB-F170-463A-ACB5-784FE23E0875 Q24187067-1A529B99-341C-4926-86BD-1CCE298787BB Q24241686-57D6A85A-7BA6-4BB8-A571-171CFF1917FE Q28551402-282037FE-B689-400A-BEE6-A0B077301AEA Q33165801-9930E1EE-3CF1-45E8-809F-DB73B8751681 Q33836947-267CFC85-F788-4A2C-8A90-115F04D63937 Q34181037-4C42D3A1-DF0C-4F3F-B686-94072C2DD25E Q34381860-6D8F9DC6-00AA-4FD3-A321-D910EF00236B Q34409349-08D3A1A9-2BD8-4D05-875B-6E760DB732CC Q34516224-61AF2C52-4D27-4ACB-BDE3-44B8D67ADE01 Q34542646-FC525CC9-A091-43CE-B822-D2E005F3CA67 Q34543707-1F234E0A-28D7-4117-B050-DE7167D1CCD5 Q34987695-228FE3CE-8C4E-4F11-9B17-7C6E73CF5F08 Q35899503-11495FDF-004F-460A-A0C6-C95C902B8F7B Q35905814-CB67FEA4-B8B8-4714-A778-2B66325B4DD6 Q36012323-EF8D3CF0-CB01-469D-BC43-76D2F69051BD Q36264977-40363A09-44BC-48DB-96A2-5282B7BE3E22 Q36288118-60516BC0-A6E7-41AE-9A7D-5A0773DA8DDE Q36383025-E4453CA4-35E4-41BF-ABA8-76646170FD1A Q36419270-D7DBE7D4-502A-4C60-A162-55DFBE1AD4D7 Q36467267-65395606-30B0-446A-B8A0-1BF07C0B3BD7 Q36515587-729DA690-20F4-4335-9874-A2FA00DE4BBD Q36766861-2006A433-56BB-42E8-9951-70FFE2ACFF74 Q37211076-D1726359-1117-4D75-ABCE-6BD9EC091B4F Q37225818-2E61E9F1-03F2-4297-B2AC-8359ABA9309D Q37316293-4D510CB8-9EB7-469B-9CAB-6CD969EC1C8C Q37358548-0AF42826-CFDA-4244-96BA-699CBF2C1A3E Q37385577-C27EE099-C081-4722-95DE-BC8A575278F5 Q37733592-AFD897CB-5343-4083-B8E1-9156BFA7574A Q37881946-CF42B0D3-8FB4-452C-A16C-61FEEB24046A Q37895257-A28C2D76-2FCD-4E20-B6CA-E5E375783235 Q37910243-C6340E24-F980-40C4-9401-B5E6F108F12A Q37942219-52AB8047-1933-40C5-8CAF-B7A73DA1EC50 Q37947768-964C39EE-C88D-4B3D-B982-EC9C327A3538 Q37952853-3C9958C9-8CEC-4D1C-877B-454EF59E9E68 Q38076109-9EADDEF8-53B0-4D03-B241-9D13125CD293 Q38127470-C3710644-7D2E-40DF-ACB2-896F0E632150 Q38247181-6EA58083-0486-4C94-BFA3-663E3B889786 Q38661735-978826A8-9106-4280-8ADA-0FA609DB782D Q38906350-ED49C384-4D8C-47FA-A860-AA654671C7CC

P2860

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

http://www.wikidata.org/entity/Q34655376

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@ast

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@en

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@nl

type

label

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@ast

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@en

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@nl

prefLabel

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@ast

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@en

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@nl

P1433

Q34655376-5FAA75E7-08BB-4E89-88FB-78907A6340D0

P1476

Q34655376-39BBB658-5BC6-43FF-BD58-69897A192FAB

P2093

Q34655376-48647149-0DD3-41E3-9422-F5AF1E77ED13

Q34655376-4942AE54-FE8B-4BAD-8396-5EA360410AD6

Q34655376-C4B8D92E-C773-4AAA-A160-E164689FB62E

Q34655376-D502859E-1493-4523-BB58-0276FF8A3124

Q34655376-DE60F53C-802D-4BD9-98F2-3444D84880ED

Q34655376-F814AE3F-1007-4B5C-B624-9ED5F2B48D1C

P304

Q34655376-24314D1E-FC5B-4D49-8810-BCD572FF45A4

P31

Q34655376-9C8D27D0-378E-4304-9A03-56553835C0DE

P356

Q34655376-0C8BDB90-6618-443F-A1A5-26B489AAE646

P407

Q34655376-23876D2E-805B-452A-B378-F7720AD15C68

P433

Q34655376-9966BC7F-21C2-4D26-ACA1-38050A0B7795

P478

Q34655376-27748D5D-93FB-4A4B-BA78-D13B98BE9D87

P50

Q34655376-BD61CEDB-3739-420D-BC3E-26830B9022FF

P577

Q34655376-7308BF23-92FF-41E8-B7C4-3A0DB027E52C

P5875

Q34655376-2FD73FEC-FE99-45BF-91DC-804EC2134A5F

P698

Q34655376-80B9E700-7E77-447A-BBBE-DA8877424A56

P921

Q34655376-B7C60FFB-89EE-413E-8506-9BC57D15FB64

Q34655376-C87A3629-88E6-4C53-ABE5-6CA45A2F6BD9

P356

01.WNL.0000281847.17519.E0

P1433

P1476

IDEAL: a 6-month, double-blind ...... n patch for Alzheimer disease.

@en

P2093

Farlow M

http://www.w3.org/2001/XMLSchema#string

Frölich L

http://www.w3.org/2001/XMLSchema#string

Grossberg G

http://www.w3.org/2001/XMLSchema#string

Lane R

http://www.w3.org/2001/XMLSchema#string

Nagel J

http://www.w3.org/2001/XMLSchema#string

Zechner S

http://www.w3.org/2001/XMLSchema#string

P304

S14-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/01.WNL.0000281847.17519.E0

http://www.w3.org/2001/XMLSchema#string

P407

P433

4 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6191328

http://www.w3.org/2001/XMLSchema#string

P698

17646619

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease